A comparison of fetal hemoglobin interference in routine high-performance liquid chromatography, immunoassay, and enzymatic methods of glycated hemoglobin measurement

Abstract Introduction Fetal hemoglobin (HbF) is known to cause method-specific interference in glycated hemoglobin A1c (HbA1c) measurement. Data on HbF interference, however, is currently either lacking for some platforms (eg, the Abbott Core Laboratory Alinity c and Beckman Coulter AU5800) or available only for HbF levels lower than the maximum claimed by the manufacturer (eg, Bio-Rad D-100). Methods We examined the effect of HbF interference on 7 HbA1c platforms using a series of spiked adult whole blood samples with increasing HbF levels (0% to 35%) and either low (approximately 5%) or high (approximately 9%) HbA1c levels, using isotope dilution mass spectrometry as a reference measurement procedure. Results For the high-performance liquid chromatography (HPLC)–based platforms (Bio-Rad VARIANT II TURBO 2.0 and D-100), relative deviation from expected values was not clinically significant, even at an HbF level of 35%. In contrast, immunoassay (AU5800; Roche Diagnostics cobas c311 and cobas b101; and Siemens Healthineers DCA Vantage) and enzymatic (Alinity c) methods showed clinically significant deviation at HbF levels above 10%. Discussion Our data suggest that the HPLC methods tested can be used for the majority of patients with elevated HbF. For patients with HbF levels above 10%, immunoassay and enzymatic methods appear to be unsuitable, and alternative HbA1c methods are still advised.